Two drugs that could help treat coronavirus Biotechnology company Gilead Sciences is halting emergency access to its experimental coronavirus drug, citing “overwhelming demand.”  The coronavirus outbreak has caused such a surge in requests for the drug, called remdesivir, that they have “flooded an emergency treatment access system that was set up for very limited access to investigational medicines,” the company said in a statement on its website. Under exceptional circumstances, the Food and Drug Administration allows companies to provide not-yet-approved drugs to people outside of clinical trials in what are known as “compassionate use” requests. Coronavirus scams claim to offer vaccines, treatment and testing The system was never designed to be used as a response to a pandemic, the company said. To stem demand, Gilead will pivot from accepting compassionate-use requests to only providing treatment through expanded access programs. Remdesivir is an antiviral drug that was originally tested in humans with the Ebola virus. It also has shown promise as a treatment for severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, known as MERS. The University of Nebraska Medical Center, in conjunction by the National Institute of Allery and Infectious Diseases, is conducting the first clinical trial of remdesivir


Continue To Full Article